Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xi Ding

Showing results (151-160 of 169) with videos related to

Pageof 17
Sort By:
The International Journal of Neuroscience|February 22, 2020
A NAC nomogram to predict the probability of three-month unfavorable outcome in Chinese acute ischemic stroke patients treated with mechanical thrombectomyXiang Li, Yang Zou, Jue Hu, et al.
Head & Neck|November 17, 2023
A novel endoscopic nasopharyngectomy by low-temperature plasma radiofrequency ablation in localized recurrent nasopharyngeal carcinomaXiong Zou, Zheng-Kai Feng, Yi-Jun Hua, et al.
Med (New York, N.Y.)|October 9, 2025
TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: An open-label, single-arm, phase II trialTian-Liang Xia, Wenxuan Huang, You-Ping Liu, et al.
Journal for Immunotherapy of Cancer|November 16, 2021
Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trialYijun Hua, Rui You, Zhiqiang Wang, et al.
Med (New York, N.Y.)|August 30, 2022
Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinomaRui You, Xiong Zou, Xi Ding, et al.
The Laryngoscope|December 30, 2020
Transoral Robotic Retropharyngeal Lymph Node Dissection in Nasopharyngeal Carcinoma With Retropharyngeal Lymph Node RecurrenceXi Ding, Qing-Guang Lin, Xiong Zou, et al.
Eclinicalmedicine|July 7, 2023
Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 studyXi Ding, Yi-Jun Hua, Xiong Zou, et al.
Iscience|May 3, 2022
Distinct miRNAs associated with various clinical presentations of SARS-CoV-2 infectionQiqi Zeng, Xin Qi, Junpeng Ma, et al.
Frontiers in Immunology|March 14, 2022
Identification of Distinct Immune Cell Subsets Associated With Asymptomatic Infection, Disease Severity, and Viral Persistence in COVID-19 PatientsXiaorui Wang, Han Bai, Junpeng Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2023
Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II StudyXi Ding, Wei-Jing Zhang, Rui You, et al.
Pageof 17

Showing results (151-160 of 169) with videos related to

Sort By:
Pageof 17
The International Journal of Neuroscience|February 22, 2020
A NAC nomogram to predict the probability of three-month unfavorable outcome in Chinese acute ischemic stroke patients treated with mechanical thrombectomyXiang Li, Yang Zou, Jue Hu, et al.
Head & Neck|November 17, 2023
A novel endoscopic nasopharyngectomy by low-temperature plasma radiofrequency ablation in localized recurrent nasopharyngeal carcinomaXiong Zou, Zheng-Kai Feng, Yi-Jun Hua, et al.
Med (New York, N.Y.)|October 9, 2025
TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: An open-label, single-arm, phase II trialTian-Liang Xia, Wenxuan Huang, You-Ping Liu, et al.
Journal for Immunotherapy of Cancer|November 16, 2021
Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trialYijun Hua, Rui You, Zhiqiang Wang, et al.
Med (New York, N.Y.)|August 30, 2022
Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinomaRui You, Xiong Zou, Xi Ding, et al.
The Laryngoscope|December 30, 2020
Transoral Robotic Retropharyngeal Lymph Node Dissection in Nasopharyngeal Carcinoma With Retropharyngeal Lymph Node RecurrenceXi Ding, Qing-Guang Lin, Xiong Zou, et al.
Eclinicalmedicine|July 7, 2023
Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 studyXi Ding, Yi-Jun Hua, Xiong Zou, et al.
Iscience|May 3, 2022
Distinct miRNAs associated with various clinical presentations of SARS-CoV-2 infectionQiqi Zeng, Xin Qi, Junpeng Ma, et al.
Frontiers in Immunology|March 14, 2022
Identification of Distinct Immune Cell Subsets Associated With Asymptomatic Infection, Disease Severity, and Viral Persistence in COVID-19 PatientsXiaorui Wang, Han Bai, Junpeng Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2023
Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II StudyXi Ding, Wei-Jing Zhang, Rui You, et al.
Pageof 17